Company intelligence / Profile preview

Ampio Pharmaceuticals, Inc.

Delaware, United Statesampiopharma.com ↗

Ownership: Public · AMPE
Employees: ~6
Development stage: Dissolved

Overview

The company's lead candidate Ampion failed to meet FDA standards in clinical trials for osteoarthritis of the knee. Their follow-up candidate OA-201 failed in preclinical animal studies in February 2024, showing inability to reduce pain caused by osteoarthritis. The company has been dissolved as of August 16, 2024, following stockholder approval of a Plan of Dissolution.

Therapeutic areas: OphthalmologyImmunologyNeurologyRheumatology
Modalities: Small molecule drugsChemical drugs
Industry: Biotech

Drug pipeline

5 assets

OA-20X

Preclinical

4 more assets in the full pipeline.

Request access →

Financials

Market cap: $207.9K
Total revenue: $245K
Enterprise value: $-3.6M

Beyond the preview

Go deeper on Ampio Pharmaceuticals, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ampio Pharmaceuticals, Inc..

Explore the full profile